CDC: HIV Prevention Pill Underutilized; Impacting North Dakota Communities

Why it matters locally: While North Dakota's overall HIV infection rates might be lower compared to larger metropolitan areas, the CDC's findings regarding PrEP underutilization are still relevant to the state. With a population of just over 780,000, even a small number of preventable HIV infections can have a significant impact on public health resources and the well-being of individuals and families. Ensuring that at-risk populations in North Dakota, particularly those in underserved communities or specific risk groups, have access to and are educated about PrEP is crucial for preventing new infections and maintaining overall public health. Furthermore, the disparities highlighted by the CDC regarding minority populations resonate in North Dakota, where disparities in healthcare access exist for certain racial and ethnic groups as well as those in rural areas. This report serves as a reminder for North Dakota's Department of Health, healthcare providers, and community organizations to evaluate current PrEP access, awareness campaigns, and targeted outreach efforts within the state. It emphasizes the need to address potential barriers to PrEP uptake, such as cost, stigma, and lack of awareness, to ensure equitable access to this preventive medication.

---

Denver, CO - A new analysis released by the Centers for Disease Control and Prevention (CDC) indicates that pre-exposure prophylaxis (PrEP), a medication used to prevent HIV infection, is not being utilized by a significant portion of the at-risk population in the United States. The findings were presented at the 2018 Conference on Retroviruses and Opportunistic Infections. The CDC analysis highlights that disparities exist in PrEP access and uptake, with people of color being disproportionately affected. Data suggests that a considerable number of individuals who could benefit from PrEP are not receiving or utilizing the medication. Further details regarding the specific methodology of the CDC analysis, the size and demographics of the study population, and specific data points on PrEP usage rates were not immediately available. Further information is expected to be released by the CDC in the near future.